Trial reportJournal of the National Cancer Institute2015
Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Journal of the National Cancer Institute, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.
- Tubal ligation and endometrial Cancer risk: a global systematic review and meta-analysis.BMC cancer · 2019Pooled it
- Role of fallopian tube and cervical canal occlusion in preventing intra-operative tumour spillage in early endometrial cancer- a pilot study.World journal of surgical oncology · 2025Trial
- BRCA1 and BRCA2 carriers: Perceptions of endometrial cancer risk.Gynecologic oncology · 2026Article
- Prospective assessment of prognostic significance of malignant peritoneal cytology in endometrial cancer: An NRG Oncology / Gynecologic Oncology Group study on GOG-210 protocol.Gynecologic oncology · 2025Article
- Prognostic significance of right subdiaphragmatic washing cytology in patients with endometrial cancer.Scientific reports · 2025Article
- The Impact of Positive Peritoneal Cytology on the Survival of Endometrial Cancer Patients.Diagnostics (Basel, Switzerland) · 2024Article
- A postoperative tumor-specific death prediction model for patients with endometrial cancer: a retrospective study.Translational cancer research · 2024Article
- Intraluminal tumor cells and prognostic accuracy of endometrial cancer stage criteria: A multi-institution study.Gynecologic oncology · 2023Article
- Prognostic Value of Peritoneal Cytology in Stage I Serous and Clear Cell Carcinoma of the Endometrium.Journal of clinical medicine · 2023Article
- A Prospective Analysis of Laparoscopic Management of Endometrial Cancer in a Tertiary Care Centre.Journal of obstetrics and gynaecology of India · 2021Article
- Targeting cancer-promoting inflammation - have anti-inflammatory therapies come of age?Nature reviews. Clinical oncology · 2021Review
- Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer.Gynecologic oncology · 2020Observational
- Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer.European journal of cancer (Oxford, England : 1990) · 2020Observational
- Pathologic Prognostic Factors in Endometrial Carcinoma (Other Than Tumor Type and Grade).International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2019Article
- Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.Gynecologic oncology · 2018Article
- Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.International journal of cancer · 2018Article
- Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer.Annals of surgical oncology · 2018Article
- Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2017Article
- Intraperitoneal cytology after laparoscopic hysterectomy in patients with endometrial cancer: A retrospective observational study.Medicine · 2017Observational
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 1 country.
Ashley S Felix: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES). ashley.felix@nih.gov.
Louise A Brinton: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
D Scott McMeekin: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
William T Creasman: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
David Mutch: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
David E Cohn: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Joan L Walker: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Richard G Moore: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Levi S Downs: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Robert A Soslow: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Richard Zaino: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Mark E Sherman: Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics (ASF, LAB) and Cancer Prevention Fellowship Program, Division of Cancer Prevention (ASF), National Cancer Institute, National Institutes of Health, Bethesda, MD; Department of Obstetrics and Gynecology, University of Oklahoma, Oklahoma City, OK (SM, JLW); Department of Obstetrics and Gynecology, Medical University of South Carolina, Charleston, SC (WTC); Washington University School of Medicine, St. Louis, MO (DM); Division of Gynecologic Oncology, Ohio State University College of Medicine, Columbus, OH (DEC); Women and Infants Hospital/Brown University, Providence, RI (RGM); University of Minnesota, Minneapolis, MN (LSD); Memorial Sloan Kettering Cancer Center, New York, NY (RAS); Anatomic Pathology, Penn State Milton S. Hersey Medical Center, Hershey, PA (RZ); Breast and Gynecologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD (MES).
Penn State Milton S. Hershey Medical Center · USUniversity of Oklahoma · USBrown University · USMedical University of South Carolina · USMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USNational Institutes of Health · USUniversity of Minnesota · US
Funding
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8MStatistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4MNRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5MGYNECOLOGIC ONCOLOGY GROUP HEADQUARTERSU10CA027469 · NCI · GYNECOLOGIC ONCOLOGY GROUP · PI DISAIA, PHILIP J. · 1985 to 2013
$132.6MHormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5MGYNECOLOGIC ONCOLOGY GROUP STATISTICAL OFFICEU10CA037517 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI BLESSING, JOHN A · 1985 to 2013
$67.4MRochester Network Lead Academic Participating SiteUG1CA233230 · NCI · UNIVERSITY OF ROCHESTER · PI Paul M Barr · 2019 to 2026
$6.9MOSU as Network Lead Academic Participating Site for the NCI NCTNU10CA180850 · NCI · OHIO STATE UNIVERSITY · PI BLUM, KRISTIE A, CHAKRAVARTI, ARNAB · 2014 to 2018
$6.8MIntramural NIH HHSNCI NIH HHS 1 U10 CA180822NCI NIH HHS CA27469NCI NIH HHS CA 37517NCI NIH HHS U10 CA027469NCI NIH HHS U10 CA037517NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180850NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA233230
Abstract
backgroundStage is a critical determinant of treatment among endometrial carcinoma patients; understanding patterns of tumor spread may suggest approaches to improve staging. Specifically, the importance of exfoliation of endometrial carcinoma cells through the fallopian tubes into the peritoneum is ill defined. We assessed the hypothesis that tubal ligation (TL), which should impede transtubal passage of cells, is associated with lower endometrial carcinoma stage at presentation and, consequently, lower mortality.
methodsThe NRG Oncology/Gynecologic Oncology Group (GOG) 210 Trial included 4489 endometrial carcinoma patients who completed a risk factor questionnaire that included TL history. Pathology data were derived from clinical reports and central review. We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for associations between TL with stage and peritoneal metastasis, overall and by tumor subtype. Cox regression was used to estimate hazard ratios (HRs) and 95% confidence intervals for TL and mortality. All statistical tests were two-sided.
resultsCompared with stage I, TL was inversely associated with stage III (OR = 0.63, 95% CI = 0.52 to 0.78) and stage IV carcinomas (OR = 0.14, 95% CI = 0.08 to 0.24) overall and among individual tumor subtypes. TL was inversely related to peritoneal metastasis overall (OR = 0.39, 95% CI = 0.22 to 0.68) and among serous carcinomas (OR = 0.28, 95% CI = 0.11 to 0.68). In multivariable models unadjusted for stage, TL was associated with lower endometrial carcinoma-specific mortality (HR = 0.74, 95% CI = 0.61 to 0.91); however, adjustment for stage eliminated the survival advantage. Similar relationships with all-cause mortality were observed.
conclusionsTL is associated with lower stage and mortality among women with aggressive endometrial carcinomas, suggesting transtubal spread is clinically important. Future studies should evaluate whether detection of intraluminal tumor cells is prognostically relevant.
Indexed as
Sterilization, TubalAdultCarcinomaCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleHumansLogistic ModelsMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPeritoneal NeoplasmsPrognosisProportional Hazards ModelsRisk Factors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.